Redeye provides a research update following the Q2 report published by Isofol earlier today. The key financials in the report did not contain any surprises and were largely in line with our estimates. However, since the end of the reporting period, the company has bolstered its cash position through an oversubscribed rights issue. With the reinitiated clinical development of arfolitixorin in full swing, we have a positive outlook on the company’s future.
LÄS MER
